Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Lymphoma 1Carcinoma, Squamous Cell 1Carcinoma, Hepatocellular 1Advanced Solid Tumor 1Advanced Pancreatic Cancer 1

Interventions

pembrolizumab 8Cetuximab 8Cisplatin 6Fluorouracil 5Paclitaxel 4durvalumab 3Radiotherapy 3Leucovorin 3Docetaxel 3Carboplatin 3tremelimumab 2niraparib 2avelumab 2Radiotherapy, Intensity-Modulated 2Pemetrexed 2Nivolumab 2Ipilimumab 2Bevacizumab 2zalutumumab 1yeast-CEA vaccine 1spartalizumab 1smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic 1regorafenib 1penpulimab 1paclitaxel poliglumex 1osimertinib 1necitumumab 1dostarlimab 1demplatin pegraglumer 1cobimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Squamous Cell × penpulimab × Clear all
NCT05783921 2023-07-28

A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2 Unknown
60 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡